Oral Route Medications to Procure 55% Market Share for Castration-Resistant Prostate Cancer (CRPC) Treatment Market | FMI Study

During the forecast period 2023 to 2033, the Castration-Resistant Prostate Cancer (CRPC) Treatment market is expected to grow at a value of 9.5% CAGR, according to Future Market Insights. By the year 2033, the global market for Castration-Resistant Prostate Cancer (CRPC) Treatment is expected to rise up to a market valuation of US$ 28 Billion. Growth of the market can be attributed to increasing prevalence of CRPC, coupled with the growing awareness and diagnosis of the disease, is one of the key drivers of this growth. In addition, the market is being driven by the introduction of novel treatments that offer better efficacy and fewer side effects than traditional therapies.

Another important factor driving the growth of the CRPC treatment market is the increasing use of combination therapies. By using a combination of different drugs and treatments, physicians can better target the cancer and improve treatment outcomes. For example, combining targeted therapies with immunotherapies has shown promise in early studies.

Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16739

One of the most promising developments in CRPC treatment is the use of targeted therapies. These drugs are designed to specifically target the cancer cells and limit their growth and spread, while minimizing damage to healthy cells. Targeted therapies such as enzalutamide and abiraterone have shown significant benefits in treating CRPC, leading to their approval by regulatory agencies around the world.

Key Takeaways from the Market Study

• Castration-Resistant Prostate Cancer (CRPC) Treatment market expected to grow at a value of 9.5% CAGR during the forecast period 2023-2033.
• By drug delivery method, oral route is expected to possess 55% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
• North America is expected to possess 46% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.
• Europe is expected to possess 40% market share for castration-resistant prostate cancer (CRPC) treatment market in 2023.

“The development of new targeted therapies, immunotherapies, and combination therapies is driving this growth, and there is significant potential for continued innovation in the years to come.” states an FMI analyst

Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-16739

Competitive Landscape

Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation

• Sanofi, a key player in CRPC treatment market is involved in the development of other drugs for the treatment of cancer more broadly, including immunotherapies and targeted therapies.
• in 2019, Abbott announced the launch of a new clinical trial to investigate the use of their drug, ABT-199, in combination with enzalutamide (Xtandi) for the treatment of metastatic CRPC. ABT-199 is a targeted therapy that works by inhibiting a protein called BCL-2, which is overexpressed in many cancer cells.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Castration-Resistant Prostate Cancer (CRPC) Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Therapy Type (Hormonal therapy, Chemotherapy, Immunotherapy, Radiotherapy) Drug Class (Antineoplastic, Non-steroidal Antiandrogen, Corticosteroids, Microtubule Inhibitor) Drug Delivery Method (Oral Route, Injectable Route) Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA)

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16739

Key Segments Profiled in the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry Survey

Therapy Type:

• Hormonal therapy
• Chemotherapy
• Immunotherapy
• Radiotherapy

Drug Class:

• Antineoplastic
• Non-steroidal Antiandrogen
• Corticosteroids
• Microtubule Inhibitor

Drug Delivery Method:

• Oral Route
• Injectable Route

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs